Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

A Retrospective Study of Prediction of 18F-FES-PET/CT Parameters on the Outcome of Palbociclib Combined With Endocrine Therapy in Patients With HR+ and HER2-metastatic Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04992156

Enrollment

Registered

2021-08-05

Start date

2017-03-15

Completion date

2022-04-15

Last updated

2022-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer

Brief summary

To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.

Interventions

DRUGPalbociclib

Palbociclib 125mg/d

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Female patients aged 18-70 years. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. HR+ was defined as estrogen receptor- or progesterone receptor-positive status by immunohistochemistry. 4. HER2 status was determined by immunohistochemistry or fluorescence in situ hybridization. 5. Palbociclib treatment of metastatic breast cancer for at least one cycle. 6. Available medical history.

Exclusion criteria

1.Incomplete medical history.

Design outcomes

Primary

Measure	Time frame
PFS	Through study completion, an expected average of 12 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026